Lasix Onyu is a drug owned by Sq Innovation Inc. It is protected by 3 US drug patents filed in 2026 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Jan 10, 2042. Details of Lasix Onyu's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US12403120 | Pharmaceutical Compositions Of Furosemide And Uses Thereof |
Jan, 2042
(15 years from now) | Active |
| US12318363 | Pharmaceutical Compositions Of Furosemide And Uses Thereof |
Jan, 2040
(13 years from now) | Active |
| US11246851 | Pharmaceutical Compositions Of Furosemide And Uses Thereof |
Jan, 2040
(13 years from now) | Active |
US patents provide insights into the exclusivity only within the United States, but
Lasix Onyu is protected by patents in multiple countries.
Understanding
the full scope
of patent protection is crucial in strategizing market entry. By looking at the broader patent
landscape, you can
identify markets with weaker patent protection which could be ideal generic entry points. The
following section offers
details on Lasix Onyu's family patents as well as insights into
ongoing legal events
on those patents.
Lasix Onyu's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Lasix Onyu:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| A Clinical Study of the Effect of MK-2828 on Rosuvastatin or Furosemide in Healthy People (MK-2828-005) | Merck Sharp & Dohme LLC | NA | COMPLETED
(Aug 1, 2026) | PHASE1 |
| Outpatient Hypertonic Saline and Loop Diuretic Combination Therapy in Cardiorenal | University of Monastir | NA | NOT YET RECRUITING
(Jul 1, 2026) | PHASE3 |
| Effect of an Isolevuglandin Scavenger on Salt Sensitivity of Blood Pressure and Immune Cell Activation in Humans | Vanderbilt University Medical Center | NA | NOT YET RECRUITING
(Jul 1, 2026) | PHASE2 |
| Early Discharge With Subcutaneous Furosemide Versus Standard Care in Acute Heart Failure | University of Texas Southwestern Medical Center | NA | NOT YET RECRUITING
(May 1, 2026) | PHASE3 |
| Comparison of Once Daily 40 mg Torsemide With Twice-daily 40 mg Furosemide | Sarfez Pharmaceuticals, Inc. | NA | TERMINATED
(Apr 1, 2026) | PHASE1 |
Generic Launch
Generic Release Date:
Lasix Onyu's generic launch date based on the expiry of its last outstanding patent is estimated to be Jan 10, 2042 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Lasix Onyu Generic API suppliers:
Furosemide is the generic name for the brand Lasix Onyu. 32 different companies have already filed for the generic of Lasix Onyu, with Watson Labs having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Lasix Onyu's generic
Alternative Brands for Lasix Onyu
There are several other brand drugs using the same active ingredient (Furosemide) as Lasix Onyu. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | ||
|---|---|---|---|
| Scpharmaceuticals |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Furosemide, Lasix Onyu's active ingredient. Check the complete list of approved generic manufacturers for Lasix Onyu
About Lasix Onyu
Lasix Onyu is a drug owned by Sq Innovation Inc. Lasix Onyu uses Furosemide as an active ingredient. Lasix Onyu was launched by Sq Innovation in 2025.
Approval Date:
Lasix Onyu was approved by FDA for market use on 07 October, 2025.
Active Ingredient:
Lasix Onyu uses Furosemide as the active ingredient. Check out other Drugs and Companies using Furosemide ingredient
Dosage:
Lasix Onyu is available in solution form for subcutaneous use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 80MG/2.67ML (30MG/ML) | SOLUTION | Prescription | SUBCUTANEOUS |